You are on page 1of 1

68148 Federal Register / Vol. 67, No.

217 / Friday, November 8, 2002 / Notices

Conference Room 10 (6th floor), Name of Committee: National Cancer Dates: December 4–5, 2002.
Bethesda, Maryland 20892. Institute Special Emphasis Panel, Minority Open: December 4, 2002, 8:45 a.m. to 3:15
Contact Person: Ann Wagner, Ph.D., Institution/Cancer Centers Partnerships: p.m.
Division of Services and Intervention CA03–009, CA03–008, CA03–010. Agenda: Program reports and
Date: December 3–4, 2002. presentations; Business of the Board.
Research, National Institute of Mental Place: National Cancer Institute, 9000
Time: 7 p.m. to 5 p.m.
Health, NIH, 6001 Executive Boulevard, Agenda: To review and evaluate grant Rockville Pike, Building 31, C Wing, 6th
Room 7142, MSC 9633, Bethesda, applications. Floor, Conference Room 10, Bethesda, MD
Maryland 20892. Email: < Place: Bethesda Marriott, 5151 Pooks Hill 20892.
awagner@mail.nih.gov > Phone: 301– Road, Bethesda, MD 20814. Contact Person: Dr. Marvin R. Kalt,
443–4283. Contact Person: Ray Bramhall, Ph.D., Executive Secretary, National Cancer
Any member of the public interested Scientific Review Administrator, Special Institute, National Institutes of Health, 6116
in presenting oral comments to the Review, Referral and Resources Branch, Executive Boulevard, 8th Floor, Room 8001,
committee may notify the contact Division of Extramural Affairs, National Bethesda, MD 20892–8327, (301) 496–5147.
person listed on this notice at least 5 Cancer Institute, National Institutes of Name of Committee: National Cancer
Health, 6116 Executive Boulevard, Suite Advisory Board, Subcommittee on Planning
days in advance of the meeting.
8060, Rockville, MD 20892, (301) 594–1403. and Budget.
Interested individuals and Open: December 4, 2002, 11:05 a.m. to
representatives of organizations may (Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction; 11:55 a.m.
submit a letter of intent, a brief Agenda: To discuss activities related to the
93.393, Cancer Cause and Prevention
description of the organization Subcommittee on Planning and Budget.
Research; 93.394, Cancer Detection and
represented, and a short description of Diagnosis Research; 93.395, Cancer
Place: National Cancer Institute, 9000
the oral presentation. Presentations may Rockvill Pike, Building 31, C Wing, 6th
Treatment Research; 93.396, Cancer Biology
be limited to 5 minutes; both printed Floor, Conference Room 10, Bethesda, MD
Research; 93.397, Cancer Centers Support;
and electronic copies are requested for 20892.
93.398, Cancer Research Manpower; 93.399,
Contact Person: Ms. Cherie Nichols,
the record. In addition, any interested Cancer Control, National Institutes of Health,
Executive Secretary, Subcommittee on
person may file written comments with HHS)
Planning and Budget, National Cancer
the committee by forwarding his/her Dated: November 1, 2002. Institute, National Institutes of Health, 9000
statement to the contact person listed on LaVerne Y. Stringfield, Rockville Pike, Building 31, Room 11A03,
this notice. The statement should Director, Office of Federal Advisory Bethesda, MD 20892, (301) 496–5515.
include the name, address, telephone Committee Policy. Name of Committee: National Cancer
number and, when applicable, the [FR Doc. 02–28533 Filed 11–7–02; 8:45 am] Advisory Board.
business or professional affiliation of Closed: December 4, 2002, 3:15 p.m. to
BILLING CODE 4140–01–M
the interested person. Recess.
Information about the meeting is also Agenda: Review intramural program site
visit outcomes; Discussion of confidential
available on-line on the NIMH Home DEPARTMENT OF HEALTH SERVICES personnel issues.
Page at < http://www.nimh.nih.gov/iacc/ Place: National Cancer Institute, 9000
index.cfm >. National Institutes of Health Rockville Pike, Building 31, C Wing, 6th
Dated: October 31, 2002. Floor, Conference Room 10, Bethesda, MD
National Cancer Institute; Notice of 20892.
Ruth L. Kirschstein,
Meeting Contact Person: Dr. Marvin R. Kalt,
Deputy Director, National Institutes of Health. Executive Secretary, National Cancer
[FR Doc. 02–28539 Filed 11–7–02; 8:45 am] Pursuant to section 10(d) of the Institute, National Institutes of Health, 6116
BILLING CODE 4140–01–P
Federal Advisory Committee Act, as Executive Boulevard, 8th Floor, Room 8001,
amended (5 U.S.C. Appendix 2), notice Bethesda, MD 20892–8327, (301) 496–5147.
is hereby given of the meeting of the Name of Committee: National Cancer
DEPARTMENT OF HEALTH AND National Cancer Advisory Board. Advisory Board.
HUMAN SERVICES The meeting will be open to the Open: December 5, 2002, 8:30 a.m. to 12
public as indicated below, with p.m.
National Institutes of Health attendance limited to space available. Agenda: Program reports and
Individuals who plan to attend and presentations; Business of the Board.
National Cancer Institute; Notice of need special assistance, such as sign Place: National Cancer Institute, 9000
Closed Meeting language interpretation or other Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
Pursuant to section 10(d) of the reasonable accommodations, should 20892.
Federal Advisory Committee Act, as notify the Contact Person listed below Contact Person: Dr. Marvin R. Kalt,
amended (5 U.S.C. Appendix 2), notice in advance of the meeting. Executive Secretary, National Cancer
is hereby given of the following A portion of the meeting will be Institute, National Institutes of Health, 6116
meeting. closed to the public in accordance with Executive Boulevard, 8th Floor, Room 8001,
The meeting will be closed to the the provisions set forth in sections Bethesda, MD 20892–8327, (301) 496–5147.
public in accordance with the 552b(c)(4), and 552b(6), as amended. Any interested person may file
provisions set forth in sections The grant applications and the written comments with the committee
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., discussions could disclose confidential by forwarding the statement to the
as amended. The grant applications and trade secrets or commercial property Contact Person listed on this notice. The
the discussions could disclose such as patentable material, and statement should include the name,
confidential trade secrets or commercial personal information concerning address, telephone number and when
property such as patentable material, individuals associated with the grant applicable, the business or professional
and personal information concerning applications, the disclosure of which affiliation of the interested person.
individuals associated with the grant would constitute a clearly unwarranted In the interest of security, NIH has
applications, the disclosure of which invasion of personal privacy. instituted stringent procedures for
would constitute a clearly unwarranted Name of Committee: National Cancer entrance into the building by non-
invasion of personal privacy. Advisory Board. government employees. Persons without

VerDate 0ct<31>2002 16:24 Nov 07, 2002 Jkt 200001 PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 E:\FR\FM\08NON1.SGM 08NON1

You might also like